Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Open-label, Phase I Trial to Determine the Safety and Tolerability of BI 3822971 in Patients With Unresectable Advanced or Metastatic Solid Cancers

NCT07744152 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07744152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07744152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Open-label, Phase I Trial to Determine the Safety and Tolerability of BI 3822971 in Patients With Unresectable Advanced or Metastatic Solid Cancers
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Recruiting
Start date
September 21, 2026
Completion date
January 15, 2030
Enrollment
137 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours